Martin Stuart Tallman

Grants

Grants per year 2000 2005 2006 2007 2020

• 53 Finished

Grants per year

Search results

• Finished

  ECOG Clinical Trials

  Benson III, A. B., Gradishar, W. J., Mulcahy, M. F., Tallman, M. S., Winter, J. N. & Yang, G.

  National Cancer Institute

  5/1/10 → 2/28/14

  Project: Research project

• PROT# 2449-US-002: Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia

  Tallman, M. S.

  Kyowa Hakko Kirin Pharma, Inc.

  11/24/09 → 11/24/12

  Project: Research project

• Prot# AEG35156-206: An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-Dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based

  Tallman, M. S.

  Aegera Therapeutics Inc.

  11/11/09 → 11/11/12

  Project: Research project

• PROT# CLTR0308-205: Phase IIB, Multicenter, Randomized, Open-Label Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Intersive Salvage Therapy in Adult Patients (equal or over)60 Years Old with AML in First Relapse Following an Initial

  Tallman, M. S.

  Celator Pharmaceuticals, Inc.

  7/6/09 → 7/6/12

  Project: Research project

• Prot# SPO-0012: Phase 1b Open-Label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-595 Injection in Combination With Cytarabine in Patients With Relapsed or Refractory Ac

  Tallman, M. S.

  Sunesis Pharmaceuticals, Inc.

  1/22/09 → 7/31/10

  Project: Research project

• Prot# CLTR0308-204: Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injections versus Cytarabine and Daunorubicin in Patients with Untreated AML 60-75 Years of Age

  Tallman, M. S.

  Celator Pharmaceuticals, Inc.

  1/20/09 → 1/19/12

  Project: Research project

• Prot# 0001A3-300-GL: Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)

  Tallman, M. S.

  Xanthus Life Sciences, Inc.

  12/2/08 → 12/1/11

  Project: Research project

• Prot# GEM016: A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered for 3 Consecutive Days Every 2 Weeks to Older Patients with Previously Untreated Acute Myeloid Leukemia (AML)

  Tallman, M. S.

  Gemin X Biotechnologies Inc.

  8/21/08 → 8/21/11

  Project: Research project

• Prot# INNO-507-P2-A1: A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy with ATRA and Arsenic Trioxide (STAR-1)

  Tallman, M. S.

  Medpace, Inc.

  4/18/08 → 8/1/13

  Project: Research project

• Prot# D2782C00007: A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1,2 and 3 in Adult Patients with Recurrent or Refractory Acute Myelogenous Leukemia

  Tallman, M. S.

  AstraZeneca Pharmaceuticals LP

  3/3/08 → 3/3/11

  Project: Research project

• Consortium for the Study of Chromatin Biology and Epigenetic Training in Hematological Malignanies

  Crispino, J. D. & Tallman, M. S.

  Leukemia & Lymphoma Society

  10/1/07 → 9/30/12

  Project: Research project

• RHLCCC: Program Leaders

  Backman, V., Catalona, W. J., Chakravarti, D., Eklund, E. A., Gordon, L. I., Green, K. J., Horvath, C. M., Khan, S. A., Kiyokawa, H., LaBonne, C., Lee, C., Longnecker, R. M., Mondragon, A., O'Halloran, T. V., Rademaker, A. W., Spring, B., Tallman, M. S. & Woloschak, G. E.

  National Cancer Institute

  9/14/07 → 7/31/13

  Project: Research project

  • cancer 100%
  • Malignant Neoplasm 64%
  • Cancer Center 43%
  • universities 33%
  • Hospital 24%

• Research on Adverse Drug Events and Reports: Novel Multiple Myeloma Drugs

  West, D. P., Belknap, S. M., Kuzel, T. M., Kwaan, H. C., McKoy, J. M., Mehta, J., Singhal, S. & Tallman, M. S.

  National Cancer Institute

  9/6/07 → 8/31/11

  Project: Research project

• Prot# SGL2003: Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

  Tallman, M. S.

  ZIOPHARM Oncology, Inc.

  6/21/07 → 6/21/10

  Project: Research project

• Prot# CAT-8015-1001: A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL)

  Tallman, M. S.

  INC Research, LLC, Cambridge Antibody Technology

  6/19/07 → 6/19/10

  Project: Research project

• Prot# AEG35156-103: An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients with Refractory/Relapsed AML in Combination with Chemotherapy

  Tallman, M. S.

  Aegera Therapeutics Inc.

  3/12/07 → 3/12/08

  Project: Research project

• Prot# H3E-US-1012: A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients with Leptomeningeal Metastases (NU prot # NU 06C2)

  Raizer, J. J., Benson III, A. B., Frankfurt, O., Gordon, L. I., Gradishar, W. J., Kuzel, T. M., Mulcahy, M. F., Patel, J. D., Tallman, M. S. & Winter, J. N.

  Lilly Research Laboratories

  12/22/06 → 9/1/14

  Project: Research project

• The Molecular Pathology of Myeloproliferative Disease

  Tallman, M. S.

  National Heart, Lung, and Blood Institute

  9/6/06 → 8/31/11

  Project: Research project

• Prot# NU 06H2: A Multicenter Phase II Study Incorporating DOXIL® and Rituximab into the Magrath Regimen for HIV-Negative and HIV-Positive Patients with Newly Diagnosed Burkitt's and Burkitt-like Lymphoma

  Frankfurt, O., Gordon, L. I., Kuzel, T. M., Mehta, J., Singhal, S., Tallman, M. S. & Winter, J. N.

  Ortho Biotech Clinical Affairs, LLC

  8/3/06 → 4/1/12

  Project: Research project

• Prot# XL999-207: A Phase 2 Study of XL999 Administered Intravenously to Subjects with Acute Myeloid Leukemia

  Tallman, M. S.

  PPD Development, Exelixis Inc.

  7/25/06 → 7/25/09

  Project: Research project

• Prot# C03002: A Phase 2 Study of Tandutinib in Patients with Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment with Standard Induction Therapy

  Tallman, M. S.

  Millennium Pharmaceuticals, Inc

  7/19/06 → 10/19/06

  Project: Research project

• Prot# NU 02Z5: Determination of Epstein Barr Virus (EBV) Load Before and After Treatment with Tyrosine Kinase or Proteasome Inhibitors: A Pilot Study

  Gordon, L. I., Benson III, A. B., Longnecker, R. M., Tallman, M. S. & Winter, J. N.

  Millennium Pharmaceuticals, Inc

  7/18/06 → 2/1/12

  Project: Research project

• Prot# X05211: A Phase II Trial of Combination Bortezomib and Rituximab as Front-Line Therapy for Low-Grade Non-Hodgkin's Lymphoma (NU Prot# NU 06H1)

  Gordon, L. I., Frankfurt, O., Kuzel, T. M., Mehta, J., Singhal, S., Tallman, M. S. & Winter, J. N.

  Millennium Pharmaceuticals, Inc

  6/29/06 → 1/31/20

  Project: Research project

• Prot# CLI-037: A Phase III Randomized Study of CLORETAZINE (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse

  Tallman, M. S.

  Ingenix Pharmaceutical Services, Inc., Vion Pharmaceuticals, Inc.

  2/8/06 → 3/1/12

  Project: Research project

• Prot# SPD758-216: An Open-Label, Single-Arm, Multi-Center, Phase 2 Study of Troxatyl (troxacitabine) Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia (AML) in Second Salvage

  Tallman, M. S.

  SGX Pharmaceuticals, Inc.

  2/3/06 → 12/27/11

  Project: Research project